RenalDevCo

RenalDevCo is a clinical-stage biotechnology company and a subsidiary of AstraZeneca, specifically established to advance the development of therapies for renal diseases. The company's primary focus is the development of zibotentan, a selective endothelin A receptor antagonist, in combination with the SGLT2 inhibitor dapagliflozin. This combination therapy is being evaluated for its potential to reduce albuminuria and improve outcomes in patients with chronic kidney disease (CKD). RenalDevCo operates as a dedicated vehicle to streamline the clinical progression of these specific renal assets within the broader AstraZeneca portfolio. The company's lead program, zibotentan + dapagliflozin, has shown promising results in the Phase 2b ZENITH-CKD trial, demonstrating significant reductions in urinary albumin-to-creatinine ratio.